Extract
Biovail Reports Second-Quarter 2009 Financial Results.
Company Records Total Revenues of $194 Million;
U.S. GAAP EPS of $0.15, Cash EPS of $0.59; Company Invests $770 Million in Q2/09; Strong Cash Flows, Recent Financings Provide Resources to Accelerate Strategy TORONTO -- Biovail Corporation (NYSE/TSX: BVF) today announced financial results for the three-month and six-month periods ended June 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these are based on the Company's current views, and actual outcomes are not certain. For more information, see the note on forward-looking information following the conference call details in this news release. "I am pleased by the progress we've made since adopting our new strategy in May 2008. The successes of the past year have solidified Biovail's near-term financial performance. The Company is building a promising development pipeline in specialty central nervous system (CNS) disorders that is required for long-term growth," said Biovail Chief Executive Officer Bill Wells. "The second quarter was particularly productive, with $770 million invested in support of our new strategy, including two acquisitions and one collaboration agreement. Our product pipeline now contains multiple development programs that target ...See the full content of this document
Sponsored links
